Welcome
 

GMO is a global investment management firm committed to providing sophisticated clients with superior asset management solutions and services. We offer a broad range of investment products, including equity and fixed income strategies across global developed and emerging markets, as well as absolute return strategies. Our client base includes endowments, pension funds, public funds, foundations and cultural institutions.

GMO is a private partnership that employs more than 550 people worldwide. Investment management is our only business. As of December 31, 2014, we managed $116 billion in client assets, $64 billion of which was in asset allocation strategies.

Our global offices include the firm's headquarters in Boston and offices in San Francisco, London, Amsterdam, Singapore, and Sydney. For more information on GMO, please see About GMO.

To read GMO's 4Q 2014 Letter, which contains Ben Inker's "Ditch the Good, Buy the Bad and the Ugly," and Jeremy Grantham's "Why Were We So Surprised? The Oil Glut, Saudi Decisions, and the Uniqueness of U.S. Fracking" please click the blue highlighted link.

(To open file, please ensure you have the most recent version of Acrobat Reader installed.)

Other recent commentary available to the public can be found by clicking on the links below:
The Case for Not Currency Hedging Foreign Equity Investments: A U.S. Investor's Perspective  -- Catherine LeGraw
De-risking Goes Beyond Interest Rate Risk: The Case for Dynamic Asset Allocation in an LDI Solution  -- Catherine LeGraw
Is Skill Dead?  -- Neil Constable and Matt Kadnar
The World's Dumbest Idea  -- James Montier
The Road Less Traveled: Minimizing Shortfall and Dynamically Allocating in DC Plans  -- James Sia
A Farmland Investment Primer  -- Julie Koeninger
Investing for Retirement: The Defined Contribution Challenge  -- Ben Inker and Martin Tarlie
In order to view other selected market commentary, please register with our website. Registering also gives you access to information about GMO's strategies as well as the GMO Trust Prospectus, Statement of Additional Information, and annual and semi-annual reports.